Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Pfizer (PFE) stock gains as company appoints James List, a former J&J (JNJ) executive as Chief Internal Medicine Officer to ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if ...

There is no better period, given the volatility in the markets today, to rotate assets into dividend stocks, said Steven ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain momentum in the near term.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Uniondale-based McHugh Furnishings, a provider of specialty furnishings for education, healthcare, entertainment and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...